14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V.

Key Points

• ABN AMRO Bank N.V. purchased 14,787 shares of Neurocrine Biosciences during the second quarter, valued at approximately $2.51 million. Institutional investors own 92.59% of the company.
• Neurocrine shares opened at $152.72, with a market capitalization of $15.52 billion and a 52-week range of $122.14 to $186.12. Insiders sold 376,612 shares worth about $59.5 million over the past three months.
• Analysts remain broadly positive, with one Strong Buy, 19 Buy, and four Hold ratings. The stock carries a “Moderate Buy” consensus rating and an average price target of $200.86.

ABN AMRO Bank N.V. bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,787 shares of the company's stock, valued at approximately $2,510,000.

Other hedge funds also recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its position in shares of Neurocrine Biosciences by 0.5% during the 1st quarter. NewEdge Advisors LLC now owns 13,066 shares of the company's stock valued at $1,721,000 after acquiring an additional 68 shares during the period. Huntington National Bank grew its holdings in shares of Neurocrine Biosciences by 12.6% in the 4th quarter. Huntington National Bank now owns 678 shares of the company's stock worth $96,000 after acquiring an additional 76 shares during the period. Motley Fool Asset Management LLC increased its stake in Neurocrine Biosciences by 4.8% in the 4th quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company's stock valued at $240,000 after purchasing an additional 78 shares in the last quarter. Main Management ETF Advisors LLC increased its stake in Neurocrine Biosciences by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company's stock valued at $1,111,000 after purchasing an additional 80 shares in the last quarter. Finally, Westpac Banking Corp increased its stake in Neurocrine Biosciences by 6.0% in the 1st quarter. Westpac Banking Corp now owns 1,615 shares of the company's stock valued at $213,000 after purchasing an additional 91 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Up 1.3%

Shares of Neurocrine Biosciences stock opened at $152.72 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The business's fifty day moving average is $167.98 and its two-hundred day moving average is $148.23. The firm has a market cap of $15.52 billion, a PE ratio of 22.39, a P/E/G ratio of 0.54 and a beta of 0.39.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 10,000 shares of the firm's stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $179.60, for a total value of $1,796,000.00. Following the sale, the insider directly owned 54,729 shares of the company's stock, valued at approximately $9,829,328.40. This trade represents a 15.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $160.25, for a total value of $1,762,750.00. Following the completion of the sale, the insider owned 25,846 shares of the company's stock, valued at $4,141,821.50. This trade represents a 29.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 376,612 shares of company stock valued at $59,493,355. Corporate insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on NBIX shares. Sanford C. Bernstein initiated coverage on Neurocrine Biosciences in a research report on Friday, May 22nd. They set an "outperform" rating and a $221.00 target price on the stock. The Goldman Sachs Group began coverage on Neurocrine Biosciences in a research report on Tuesday, June 2nd. They issued a "buy" rating and a $213.00 price target for the company. Piper Sandler lifted their price target on Neurocrine Biosciences from $207.00 to $210.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. BMO Capital Markets boosted their price objective on shares of Neurocrine Biosciences from $144.00 to $170.00 and gave the stock a "market perform" rating in a research report on Monday, July 13th. Finally, Wells Fargo & Company increased their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $200.86.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source